Reuters logo
BRIEF-Transgene receives FDA approval to begin clinical trials in first-line treatment of lung cancer‍​
September 11, 2017 / 4:16 PM / 14 days ago

BRIEF-Transgene receives FDA approval to begin clinical trials in first-line treatment of lung cancer‍​

Sept 11 (Reuters) - TRANSGENE SA:

* RECEIVES FDA IND APPROVAL TO BEGIN CLINICAL TRIAL WITH TG4010 + NIVOLUMAB + CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF LUNG CANCER‍​

* FIRST PATIENT IS EXPECTED TO BE INCLUDED INTO THIS PHASE 2 STUDY AT THE END OF 2017

* THE PHASE 2 TRIAL WILL EVALUATE OBJECTIVE TUMOR RESPONSES AND DISEASE CONTROL

* THE STUDY WILL ALSO ASSESS THE SAFETY AND TOLERABILITY OF THE REGIMEN TOGETHER WITH OTHER EFFICACY PARAMETERS

* THIS MULTI-CENTER SINGLE-ARM TRIAL WILL ENROLL PATIENTS BOTH IN THE USA AND EUROPE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below